START: A European state-of-the-art on-line instrument for clinical oncologists

P. Casali, L. Licitra, C. Tondini, F. De Braud, P. Bruzzi, A. Costa, F. Cavalli

Research output: Contribution to journalArticle

Abstract

START ('State-of-the-Art Oncology in Europe'), a freely available resource on the Internet, is a European 'information base' of current clinical approaches to human tumours. Its aim is to help clinical oncologists make appropriate clinical decisions by providing them with updated information reflecting state-of-the-art cancer treatment as perceived by the European oncology community. It is based upon contributions from authors and internal reviewers from all over Europe as selected by START's editorial board under the supervision of an advisory board and a scientific committee. Close collaborations with the main European cancer societies are ongoing. An external feedback process augments the mechanisms for rendering START a truly European instrument. START is concerned with evidence-based cancer medicine, and the main clinical options are thus codified and their bases indicated in accord with a scale worked out from the perspective of clinical decision- making. Therapeutic options may be 'standard', 'investigational', or 'suitable for individual clinical use' (within the context of a decision made jointly by the patient and the physician). The goal of instruments such as START is to improve the quality of patient care. In addition, START hopes to make contributions to the methodology by which medical research is transformed into clinical decisions.

Original languageEnglish
Pages (from-to)769-773
Number of pages5
JournalAnnals of Oncology
Volume10
Issue number7
DOIs
Publication statusPublished - 1999

Keywords

  • Decision making
  • Diffusion of innovation
  • Evidence-based medicine
  • Neoplasms/diagnosis
  • Neoplasms/therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'START: A European state-of-the-art on-line instrument for clinical oncologists'. Together they form a unique fingerprint.

  • Cite this